bioRxiv ScienceSearch

bioRxiv · 10.1101/503359

Molecular Process Diagram: a precise, scalable and compact visualization of rule-based models

Abstract

Rule-based modeling allows representation and simulation of biological systems where molecular features (such as protein domains) and feature-specific details of molecular interactions are accounted for. The rule-based description is precise and can define very fine molecular details (e.g. how phosphorylation status of a single residue in a multi-protein complex can affect affinity of another binding site of another protein within the same complex), but makes it difficult to effectively combine the assumptions scribed within the multiple rules of a model into a diagrammatic view. Various visualization schemas have been suggested, but they are all highly rule-based centric (e.g. a visual list of unconnected rules, extended contact maps, or atom-rule graphs). None of them match the clarity of traditional reaction/pathway diagrams, where a researcher can easily visually track the transitions and modifications of chemical species occurring in the biological systems being modeled. Here we present a novel approach and software for precise, scalable and compact representation of rule-based models that we call Molecular Process Diagram. It is based on the three basic elements: interacting molecular complexes, molecular sites directly modified by a rule, and molecular sites that are not modified but contribute to a rule mechanism (e.g. a site that in a phosphorylated state changes binding affinity of another site). Multiple levels of resolution are available: pathway-like diagram of interactions among molecules, optional site-specific interactions, and additional contingencies for interactions. Inclusion of molecular sites enables unambiguous reconstruction of the rule descriptions from the visual diagram without additional supporting documentation, while still keeping a pathway-like visual appearance. The proposed approach for visualization has been implemented in the Virtual Cell (VCell) modeling and simulation framework. Our Molecular Process Diagrams extend the notion of Systems Biology Graphical Notation (SBGN) process diagrams and use SBGN-compliant conventions.\n\nSummaryKinetic models have provided significant insights into biological regulatory mechanisms even though they typically did not take into consideration the details of protein subcomponents such as binding domains and phosphorylation sites. However, these details are often required for an accurate understanding of the events that occur during cell signaling. Without such detailed understanding, intervention strategies to act on signaling pathways in pathological conditions are bound to have limited success. This need to include site-specific details into models led to the advance of rule-based modeling. While rules describe the details of interactions with unmatched precision, they often obscure the \"big picture\", i.e. a pathway-like description of the information flow through the biological system. An intuitive visual diagram is crucial for understanding the assumptions embodied into a model. Here we present a novel approach and software for precise, scalable and compact representation of rule-based models that we call Molecular Process Diagram. It allows visualizing in a pathway-like diagram of the interacting molecules, the molecular sites modified, and the molecular sites that affect the interactions. The approach is implemented in the Virtual Cell (VCell) modeling and simulation framework and suggested as an extension for the Systems Biology Graphical Notations (SBGN) standard.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Vasilescu, D., Greene, J., Schaff, J. C., Moraru, I. I., Blinov, M. L.. 2018-12-21. Molecular Process Diagram: a precise, scalable and compact visualization of rule-based models. https://doi.org/10.1101/503359

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

INFORME: coupling information-theoretic experimental design with nonlinear mixed-effects modeling for efficient observation scheduling

Mathematical models of treatment response can inform individualized therapy, but their calibration often requires longitudinal measurements that are costly, burdensome, and collected on fixed schedules. Such schedules may be inefficient, over-sampling patients whose response is already well characterized while delaying informative measurements for those whose model parameters remain uncertain. We present INFORME (INFORmation-theoretic design with Mixed Effects), a framework that combines Bayesian information-theoretic experimental design with nonlinear mixed-effects modeling to adaptively select each patients next measurement time. Population and response-subgroup parameter distributions learned from an existing cohort provide informative priors, allowing candidate measurement times to be ranked by their expected reduction in patient-specific parameter uncertainty. As observations accumulate, priors can be updated to reflect the response subgroup most consistent with the patients data. We evaluate INFORME in two radiotherapy datasets: 150 synthetic tumor volume trajectories from a hybrid cellular automaton model of prostate cancer spheroids (HD1) and longitudinal tumor volumes from 39 patients with head-and-neck cancer (HD2). In HD1, population priors allowed omission of both pretreatment scans, while adaptive scheduling reduced the protocol from nine scans to three or four, with the response group identified from a single post-treatment scan on day 27. In HD2, the adaptive schedule used three scans instead of six and improved prediction by delaying the first on-treatment scan from week 1 to week 2, avoiding transient dynamics that produced false-positive and false-negative response projections. Across both datasets, the adaptive schedules used a mean of 2.7 scans in stead of seven and advanced completion of the patient-specific prediction by a mean of 15.5 days (95% CI, 6.7-24.3) relative to the equidistant protocol, while treatment duration remained unchanged. INFORME therefore reduces measurement burden and accelerates patient-specific prediction by concentrating observations at times that are most informative for model calibration.

systems biology

Sobetirome, a thyroid hormone receptor beta agonist, is a potential therapeutic agent for pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with limited treatment options. Our group previously identified the antifibrotic potential of thyroid hormone, triiodothyronine (T3); however, clinical translation of thyroid hormone therapy is limited by its systemic adverse effects. In this study, we investigate whether sobetirome, a selective and well tolerated thyroid hormone receptor beta (THRB) agonist, offers antifibrotic benefits of thyroid hormone while minimizing systemic toxicity. Our study reveals that sobetirome, administered via intraperitoneal or inhalational routes, effectively mitigates bleomycin-induced pulmonary fibrosis in mice, with no evidence of toxicity. We identified that sobetirome restores mitochondrial homeostasis via activating the THRB-PPARGC1a axis. This protects alveolar type II epithelial cells from injury-induced apoptosis while selectively inducing apoptosis and metabolic reprogramming in apoptosis resistant IPF fibroblasts. Cell-specific deletion of Ppargc1a in either alveolar epithelial cells or fibroblasts abolishes sobetirome-mediated protection, establishing PPARGC1a as an essential mediator of therapeutic response. Importantly, sobetirome reverses fibrosis-associated transcriptional programs in human IPF lung tissue, reducing expression of key fibrosis-associated genes, including collagen I alpha 1 (COL1A1), collagen III alpha 1 (COL3A1), periostin (POSTN), cathepsin K (CTSK), and Chitinase 3 Like 1 (CHI3L1), while promoting extracellular matrix remodeling, epithelial restoration, and tissue homeostasis. Collectively, our findings identify THRB activation as a novel metabolic strategy for reversing pulmonary fibrosis. Across complementary in vitro, in vivo, and human ex vivo models, sobetirome restores mitochondrial function, modulates apoptotic pathways in pathogenic cells, and promotes fibrosis resolution, highlighting its potential as a lung-targeted therapeutic approach for IPF and other fibrotic lung diseases.

systems biology

Mechanistic modeling of bacterial translation initiation across growth conditions

Translation frequency in bacteria depends on how ribosomes, mRNAs, and initiation factors are allocated across growth conditions. Here, we developed a mechanistic ODE-based model of Escherichia coli translation that represents initiation, elongation, termination, and coupled auxiliary processes. Growth-dependent abundances were derived from physiological relationships and reprocessed omics data, and simulated outputs were compared with translation-frequency and active-ribosome references. The model predicts a continuous shift from complex-formation-limited toward ribosome-limited behavior as growth increases. This shift is characterized by a decline in free-ribosome abundance, whereas initiation-factor pools remain largely unbound and do not become depleted in parallel. Together with the implemented IF-dependent kinetic term, this preserved availability provides a model-internal route through which productive initiation can be maintained despite increasing ribosome utilization. Consistently, transcript-wide ribosome loading remains below its theoretical maximum, while COG-level simulations reveal distinct sector-specific translation-frequency trajectories. The study therefore provides a resource-allocation framework for interpreting how mRNA--ribosome interactions shape bacterial translation across growth conditions.

systems biology